A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2‐receptor agonist.
Open Access
- 1 October 1989
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 28 (4) , 435-441
- https://doi.org/10.1111/j.1365-2125.1989.tb03524.x
Abstract
1. SK&F 101468, a non phenolic indolone derivative, has been characterised preclinically as a novel, potent and specific dopamine D2‐ receptor agonist. 2. Its tolerability and effects on serum prolactin were investigated in 14 healthy male volunteers in a study of the first administration of SK&F 101468 to man. 3. Doses between 80 micrograms and 2.5 mg caused statistically significant (P less than 0.05) lowering of basal and food stimulated serum prolactin, relative to placebo, over a 6 h post treatment period. 4. SK&F 101468 was well tolerated up to 1 mg with symptoms of nausea and postural hypotension at higher doses.Keywords
This publication has 30 references indexed in Scilit:
- 4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone: a prejunctional dopamine receptor agonistJournal of Medicinal Chemistry, 1985
- Two dopamine receptors: Biochemistry, physiology and pharmacologyLife Sciences, 1984
- Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.BMJ, 1983
- Propylbutyldopamine: hemodynamic effects in conscious dogs, normal human volunteers and patients with heart failure.Circulation, 1983
- Failure of naloxone to reverse apomorphine effects in humansPsychoneuroendocrinology, 1983
- Metabolic clearance and production rates of prolactin in man.Journal of Clinical Investigation, 1979
- The effects of bromocriptine on pre-synaptic and post-synaptic α-adrenoceptors in the mouse vas deferensJournal of Pharmacy and Pharmacology, 1979
- Area postrema: Chemoreceptor trigger zone for vomiting - is that all?Life Sciences, 1974
- PREVENTION OR REVERSAL OF LEVODOPA-INDUCED CARDIAC ARRHYTHMIAS BY DECARBOXYLASE INHIBITORSThe Lancet, 1970